NewAmsterdam Pharma Stock Soars on Positive Phase 3 Trial Results
NewAmsterdam Pharma (NASDAQ: NAMS) stock surged over 30% on Tuesday following the release of positive topline data from its Phase 3 BROADWAY clinical trial. The trial evaluated the efficacy and safety of obicetrapib, an oral, once-daily CETP inhibitor, in patients […]
NewAmsterdam Pharma Stock Soars on Positive Phase 3 Trial Results Read More »